BDX Stock Overview
BCAL Diagnostics Limited, a biotechnology company, engages in developing a non-invasive laboratory blood test for the detection of breast cancer.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
My Notes
NewNotes are coming soon
BCAL Diagnostics Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.06 |
52 Week High | AU$0.15 |
52 Week Low | AU$0.059 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | -9.09% |
1 Year Change | -42.86% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -76.00% |
Recent News & Updates
Shareholder Returns
BDX | AU Biotechs | AU Market | |
---|---|---|---|
7D | 0% | -1.4% | 0.6% |
1Y | -42.9% | 11.8% | 3.5% |
Return vs Industry: BDX underperformed the Australian Biotechs industry which returned 11.8% over the past year.
Return vs Market: BDX underperformed the Australian Market which returned 3.5% over the past year.
Price Volatility
BDX volatility | |
---|---|
BDX Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 9.1% |
Market Average Movement | 8.5% |
10% most volatile stocks in AU Market | 15.7% |
10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: Insufficient data to determine BDX's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine BDX's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | n/a | John Hurrell | https://www.bcaldiagnostics.com |
BCAL Diagnostics Limited, a biotechnology company, engages in developing a non-invasive laboratory blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vesicles from a patient's plasma or blood sample to diagnose the presence of breast cancer cells in a patient’s body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
BCAL Diagnostics Limited Fundamentals Summary
BDX fundamental statistics | |
---|---|
Market Cap | AU$12.69m |
Earnings (TTM) | -AU$3.39m |
Revenue (TTM) | AU$718.67k |
17.7x
P/S Ratio-3.7x
P/E RatioIs BDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BDX income statement (TTM) | |
---|---|
Revenue | AU$718.67k |
Cost of Revenue | AU$0 |
Gross Profit | AU$718.67k |
Other Expenses | AU$4.10m |
Earnings | -AU$3.39m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -0.016 |
Gross Margin | 100.00% |
Net Profit Margin | -471.08% |
Debt/Equity Ratio | 0% |
How did BDX perform over the long term?
See historical performance and comparison